WO2010111264A3 - Rasagiline formulations - Google Patents
Rasagiline formulations Download PDFInfo
- Publication number
- WO2010111264A3 WO2010111264A3 PCT/US2010/028314 US2010028314W WO2010111264A3 WO 2010111264 A3 WO2010111264 A3 WO 2010111264A3 US 2010028314 W US2010028314 W US 2010028314W WO 2010111264 A3 WO2010111264 A3 WO 2010111264A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rasagiline
- formulations
- pharmaceutically acceptable
- salt
- aspects relate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to pharmaceutical formulations comprising rasagiline, or a pharmaceutically acceptable salt thereof. Aspects relate to formulations prepared using rasagiline or a salt with a particle size distribution wherein about 90% of the particles have particle sizes smaller than 1000 μm, and having content uniformity such that the formulation contains 90% to 110% of the label content of rasagiline or its salt. Further aspects relate to stable pharmaceutical formulations comprising rasagiline or a pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient, wherein the formulations are substantially free of a sugar alcohol.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN658/CHE/2009 | 2009-03-24 | ||
| IN658CH2009 | 2009-03-24 | ||
| US18651809P | 2009-06-12 | 2009-06-12 | |
| US61/186,518 | 2009-06-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2010111264A2 WO2010111264A2 (en) | 2010-09-30 |
| WO2010111264A3 true WO2010111264A3 (en) | 2011-02-24 |
Family
ID=42781817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2010/028314 Ceased WO2010111264A2 (en) | 2009-03-24 | 2010-03-23 | Rasagiline formulations |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2010111264A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010274589A1 (en) * | 2009-07-23 | 2012-02-16 | Alkem Laboratories Ltd. | Oral pharmaceutical composition of rasagiline and process for preparing thereof |
| EP2389927A1 (en) * | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of rasagiline |
| WO2012153349A2 (en) | 2011-05-04 | 2012-11-15 | Cadila Healthcare Limited | Rasagiline and its pharmaceutically acceptable salts |
| DE102012000786A1 (en) * | 2012-01-18 | 2013-07-18 | Stada Arzneimittel Ag | Process for the preparation of a solid pharmaceutical composition containing the active substance rasagiline |
| WO2013175493A1 (en) | 2012-04-09 | 2013-11-28 | Cadila Healthcare Limited | Stable oral pharmaceutical compositions |
| WO2014192022A1 (en) * | 2013-05-20 | 2014-12-04 | Cadila Healthcare Limited | Pharmaceutical compositions of rasagiline |
| EP3274348A4 (en) | 2015-03-26 | 2018-08-22 | Unichem Laboratories Limited | Process of preparing potassium salt of azilsartan medoxomil |
| RU2018137590A (en) * | 2016-03-26 | 2020-04-27 | Др. Редди'С Лабораторис Лтд. | PHARMACEUTICAL COMPOSITIONS FOR N-PROPARGYLAMINE DERIVATIVE |
| CN114469902B (en) | 2020-10-23 | 2024-10-29 | 上海上药中西制药有限公司 | Sublingual film agent of rasagiline or medicinal salt thereof, and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006014973A2 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| WO2006057912A2 (en) * | 2004-11-24 | 2006-06-01 | Teva Pharmaceutical Industries, Ltd. | Rasagiline orally disintegrating compositions |
| WO2006091657A1 (en) * | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
-
2010
- 2010-03-23 WO PCT/US2010/028314 patent/WO2010111264A2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006014973A2 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| WO2006057912A2 (en) * | 2004-11-24 | 2006-06-01 | Teva Pharmaceutical Industries, Ltd. | Rasagiline orally disintegrating compositions |
| WO2006091657A1 (en) * | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010111264A2 (en) | 2010-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010111264A3 (en) | Rasagiline formulations | |
| WO2013130669A8 (en) | Pharmaceutical composition and administration thereof | |
| WO2011106416A3 (en) | Abuse-resistant formulations | |
| WO2009122301A3 (en) | Rasagiline mesylate particles and process for the preparation thereof | |
| WO2009092129A8 (en) | Delayed release pharmaceutical composition of duloxetine | |
| WO2011124953A3 (en) | Controlled release pharmaceutical compositions of tapentadol | |
| WO2012021715A3 (en) | Stable formulations of linaclotide | |
| WO2009074286A3 (en) | Pharmaceutical formulation comprising ezetimibe | |
| MX2012001939A (en) | Pharmaceutical composition and administrations thereof. | |
| BR112013026363A2 (en) | nanosuspensions of freeze-dried drug | |
| WO2011076749A3 (en) | Solid pharmaceutical dosage form of ticagrelor | |
| WO2010000877A3 (en) | Formulation with irritation reducing action comprising bisabolol and [6]-paradol | |
| WO2009050726A3 (en) | Compositions and methods for improved delivery of bupropion | |
| NZ721952A (en) | Delayed release compositions of linaclotide | |
| HK1213174A1 (en) | Stable aqueous formulations of etanercept | |
| WO2010021607A3 (en) | Pharmaceutical formulation | |
| WO2013057741A3 (en) | Pharmaceutical compositions of ursodeoxycholic acid | |
| WO2011067667A3 (en) | Fexofenadine microcapsules and compositions containing them | |
| WO2011143118A3 (en) | Alcohol-resistant formulations | |
| MX2023006856A (en) | Dry powder compositions with magnesium stearate. | |
| WO2012035283A8 (en) | Pharmaceutical composition | |
| HK1220445A1 (en) | Compositions with thixotropy and enhanced dissolution reproducibility and stability | |
| WO2012087255A3 (en) | Pharmaceutical formulations comprising imatinib | |
| HK1209371A1 (en) | Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same | |
| WO2012085284A3 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10756713 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 10756713 Country of ref document: EP Kind code of ref document: A2 |